Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* aPAP diagnosed by computed tomography, or by biopsy, or by Broncho Alveolar Lavage (BAL), and by increased GM-CSF autoantibodies in serum.~* Stable or progressive aPAP during a minimum period of 2 months prior to the Baseline visit.~* Arterial oxygen tension (PaO2) \<75 mmHg/\<10 kilo Pascal (kPa) at rest, OR desaturation of \>4 percentage points on the 6MWT~* An alveolar-arterial oxygen difference \[(A-a)DO2\] of minimum 25 mmHg/3.33 kPa~* Female or male ≥18 years of age~* Females who have been post-menopausal for \>1 year or females of childbearing potential after a confirmed menstrual period using a highly efficient method of contraception (i.e. a method with \<1% failure rate such as combined hormonal contraception, progesterone-only hormonal contraception, intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinence), during and until 30 days after last dose of double-blind trial treatment. Females of childbearing potential must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at dosing at Baseline (Visit 2) and must not be lactating~* Males agreeing to use condoms during and until 30 days after last dose of double-blind medication, or males having a female partner who is using adequate contraception as described above~* Willing and able to provide signed informed consent~* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures specified in the protocol as judged by the investigator~Exclusion Criteria:~* Diagnosis of hereditary or secondary PAP~* WLL within 1 month of Baseline~* Treatment with GM-CSF within 3 months of Baseline~* Treatment with rituximab within 6 months of Baseline~* Treatment with plasmapheresis within 3 months of Baseline~* Treatment with any investigational medicinal product within 4 weeks of Screening~* Concomitant use of sputum modifying drugs such as carbocysteine or ambroxol~* History of allergic reactions to GM-CSF~* Connective tissue disease, inflammatory bowel disease or other autoimmune disorder requiring treatment associated with significant immunosuppression, e.g. more than 10 mg/day systemic prednisolone~* Previous experience of severe and unexplained side-effects during aerosol delivery of any kind of medicinal product~* History of, or present, myeloproliferative disease or leukaemia~* Known active infection (viral, bacterial, fungal or mycobacterial)~* Apparent pre-existing concurrent pulmonary fibrosis~* Any other serious medical condition which in the opinion of the investigator would make the participant unsuitable for the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-blind molgramostim once daily (Type: EXPERIMENTAL): Inhalation of molgramostim nebuliser solution 300 mcg once daily for 24 weeks
- Double-blind molgramostim intermittent (Type: EXPERIMENTAL): Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 weeks (12 cycles)
- Double-blind placebo (Type: PLACEBO_COMPARATOR): Inhalation of placebo nebuliser solution once daily for 24 weeks
- Open-label molgramostim intermittent (Type: EXPERIMENTAL): Inhalation of molgramostim nebuliser solution 300 mcg for 7 days and placebo nebuliser solution for 7 days for 24 or 48 weeks from completion of the double-blind period

Based on this trial design, predict the completion outcome and termination type (if applicable).